Chronic Urticaria Or Hives - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 65 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2016, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 4, 2 and 3 respectively for Chronic Urticaria Or Hives.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Urticaria Or Hives Overview 7
Therapeutics Development 8
Pipeline Products for Chronic Urticaria Or Hives - Overview 8
Chronic Urticaria Or Hives - Therapeutics under Development by Companies 9
Chronic Urticaria Or Hives - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Chronic Urticaria Or Hives - Products under Development by Companies 13
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development 14
Biofrontera AG 14
ELORAC, Inc. 15
F. Hoffmann-La Roche Ltd. 16
Genentech, Inc. 17
GlaxoSmithKline Plc 18
Mabtech Limited 19
Mycenax Biotech Inc. 20
Novartis AG 21
Panacea Biotec Limited 22
Synermore Biologics Co Ltd 23
Chronic Urticaria Or Hives - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
BF-Derm-1 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
cidoxepin hydrochloride - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
GSK-2646264 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
JDP-205 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
ligelizumab - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
omalizumab - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
omalizumab biosimilar - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
omalizumab biosimilar - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
omalizumab biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
omalizumab biosimilar - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
omalizumab biosimilar - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
quilizumab - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Chronic Urticaria Or Hives - Dormant Projects 50
Chronic Urticaria Or Hives - Discontinued Products 51
Chronic Urticaria Or Hives - Product Development Milestones 52
Featured News & Press Releases 52
Jun 12, 2015: Novartis reports new analysis showing Xolair improving quality of life by 78% for chronic spontaneous urticaria patients 52
Aug 28, 2014: Novartis announces that Xolair is approved in Canada as a licensed therapy for chronic idiopathic urticaria (CIU) patients unresponsive to antihistamines 53
May 07, 2014: FDA Approves Xolair for Treatment of Chronic Hives 54
Mar 21, 2014: Novartis announces US FDA approval of Xolair for chronic idiopathic urticaria 54
Mar 06, 2014: Novartis announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines 55
Jan 24, 2014: Novartis reports positive opinion from CHMP for Xolair in severe form of skin disease CSU, a debilitating form of hives and chronic itch 56
Oct 11, 2013: FDA Files Genentech's Supplemental Biologics License Application of Xolair for Chronic Idiopathic Urticaria 58
Sep 30, 2013: Novartis to reveal landmark Phase III results of omalizumab at upcoming EADV 2013 congress 59
Jun 26, 2013: Novartis Reports New Phase III Data Showing Omalizumab Significantly Improves Itch In Patients With Severe Form Of CSU 60
Mar 20, 2013: Omalizumab Shows Promise In Eliminating Symptoms Of Chronic Urticaria, Study Finds 61
Feb 24, 2013: Genentech Reports Omalizumab Meets Primary Endpoint In Phase III Results In Patients With Chronic Form Of Hives Who Failed Standard Therapy 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 64
Disclaimer 65

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Chronic Urticaria Or Hives - Pipeline by Biofrontera AG, H2 2016 14
Chronic Urticaria Or Hives - Pipeline by ELORAC, Inc., H2 2016 15
Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 16
Chronic Urticaria Or Hives - Pipeline by Genentech, Inc., H2 2016 17
Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H2 2016 18
Chronic Urticaria Or Hives - Pipeline by Mabtech Limited, H2 2016 19
Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc., H2 2016 20
Chronic Urticaria Or Hives - Pipeline by Novartis AG, H2 2016 21
Chronic Urticaria Or Hives - Pipeline by Panacea Biotec Limited, H2 2016 22
Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Chronic Urticaria Or Hives - Dormant Projects, H2 2016 50
Chronic Urticaria Or Hives - Discontinued Products, H2 2016 51